Evidence map›Paper›PMID 28296761›Full record

SynthesisMedicine2017

Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis.

Qi Qiu, Jing Huang, Yang Lin, Xiaoming Shu, Huizheng Fan, Zhihua Tu, Youwen Zhou, Cheng Xiao

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Biomedicines · 2023
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Qi QiuInstitute of Clinical Pharmacology, Beijing Anzhen Hospital, Capital Medical University Institute of Clinical Medicine, China-Japan Friendship Hospital Beijing University of Chinese Medicine Department of Rheumatology, China-Japan Friendship Hospital, Beijing Department of Gastroenterology, People's Hospital of Yichun, Jiangxi Yichun Department of Rheumatology, Yili Kazak Autonomous Prefecture Hospital of Traditional Chinese Medicine, Xinjiang Yining, China Department of Dermatology and Skin Science, University of British Columbia Molecular Medicine Lab and Chieng Genomics Center, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada.
Jing Huang
Yang Lin
Xiaoming Shu
Huizheng Fan
Zhihua Tu
Youwen Zhou
Cheng Xiao
Med Data Quest (United States) · USChina-Japan Friendship Hospital · CNSKiN Health · CAYichun University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMethotrexate (MTX) is widely used and considered a first-line disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). However, 10% to 30% of patients discontinue therapy within a year of starting the treatment, usually because of undesirable side effects. Many of the relevant genes have been investigated to estimate the association between gene polymorphisms and MTX toxicity in RA patients, although inconsistent results have been reported.

methodsWe searched EMBASE and PubMed in February 2016 for polymorphisms and pharmacogenomics study of the toxicity of MTX monotherapy in RA patients. The meta-analysis was stratified by whether genetic variants associated with MTX toxicity.

resultsA total of 42 publications that included 28 genes with 88 gene SNPs associated with the transporters, enzymes, and metabolites of MTX or the progression of RA were included in the SR, and 31 studies were included in 7 meta-analyses. The meta-analysis showed a significant association between the toxicity of MTX and the RFC-1 80G > A (rs1051266) polymorphism in the European RA patients.

conclusionRFC-1 80G > A (rs1051266) polymorphism was associated with MTX toxicity, and larger and more stringent study designs may provide more accurate results for the effect of these SNPs on the MTX toxicity.

Indexed as

5-Methyltetrahydrofolate-Homocysteine S-MethyltransferaseAntirheumatic AgentsArthritis, RheumatoidATP Binding Cassette Transporter, Subfamily BBiomarkersFerredoxin-NADP ReductaseHumansHydroxymethyl and Formyl TransferasesMethotrexateMethylenetetrahydrofolate Reductase (NADPH2)Multienzyme ComplexesNucleotide DeaminasesPharmacogeneticsPolymorphism, Single NucleotideReplication Protein C5-Methyltetrahydrofolate-Homocysteine S-MethyltransferaseABCB1 protein, humanAntirheumatic AgentsATP Binding Cassette Transporter, Subfamily BBiomarkersFerredoxin-NADP ReductaseHydroxymethyl and Formyl Transferasesinosine monophosphate synthasemethionine synthase reductaseMethotrexateMethylenetetrahydrofolate Reductase (NADPH2)MTHFR protein, humanMTR protein, humanMultienzyme ComplexesNucleotide DeaminasesReplication Protein CRFC1 protein, human

Identifiers

PMID28296761
PMCPMC5369916
OpenAlexW2625066871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.